Nintedanib-induced lichenoid drug eruption: a case report.
Mathur M, Paudel S, Karki S, Bhattarai N, Shrestha S, Regmi S
Skin Health and DiseaseIn the feed 1 Aug 2026, published online 7 May 2026, issue 2026 Aug, added to PubMed 1 Aug 2026
Topics: Lichen planus & lichenoidDrug reactions
Abstract
Lichenoid drug eruption is a cutaneous adverse reaction that resembles lichen planus but is distinguished by marked polymorphism, including lichenoid, psoriasiform and eczematous lesions. It is a type IV hypersensitivity reaction that has been -associated with the use of numerous medications, including angiotensin-converting enzyme inhibitors, thiazide diuretics, antimalarials and beta blockers. Nintedanib works as an intracellular inhibitor of tyrosine kinases, targeting numerous receptors, including vascular endothelial growth factor, fibroblast growth factor and platelet-derived growth factor. We report a case of lichenoid drug eruption secondary to nintedanib. This association has not previously been described in the literature.
Abstract from PubMed
PMID 42540098 · DOI 10.1093/skinhd/vzag051